巨子 ICON - 財經股票資訊及專家分析
搜尋 股票

Relmada Therapeutics

RLMD
最少15分鐘延遲,股票資訊由第三方資訊供應商提供
・Relmada Therapeutics - 延遲價格・最後更新於 14/01 12:15
最高位
19.920
最低位
18.210
開市價
--
前收市價
18.730
成交量(千)
6.00
成交額(百萬)
1.09
買入
--
賣出
--
每手股數
--
市值(百萬)
548.98
市盈率
--
息率
--
差價
--
52週高低
40.000 - 16.340
所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

企業資料

公司名稱
Relmada Therapeutics
證券代碼
RLMD.US
所屬板塊
Biotechnology
公司業務
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.
發行量
16747289
公司總部
880 Third Avenue, 12th Floor
公司網址
https://www.relmada.com
公司電郵
straversa@relmada.com
公司電話
+1 646 876-3459
暫無內容

關於

Relmada Therapeutics(RLMD.US)所屬的行業板塊為Biotechnology。
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.
詳細公司背景可參考: https://www.relmada.com